North America RNAi Therapeutics Market
Historic Data:    |   Base Year: 2023   |   Forecast Period: 2024-2031
Forecast to 2027 - COVID-19 Impact and Regional Analysis By Molecule Type (Small Interfering RNAs (siRNA) and MicroRNA (miRNA)); Application (Genetic Disorders, Oncology, Neurodegenerative Disorders, Cardiovascular, Respiratory Disorders, Infectious Diseases, Renal Diseases, and Other); Route of Administration (Intradermal Injections, Pulmonary Delivery, Intravenous Injections, Intraperitoneal Injections, and Others); and End User (Diagnostic Laboratories, Research and Academic Laboratories, and Hospitals)

No. of Pages: 123    |    Report Code: TIPRE00015136    |    Category: Life Sciences

Available Report Formats

pdf-format excel-format pptx-format
Request Free Sample Buy Now
North America RNAi Therapeutics Market
Free Sample Buy Now

1. Introduction

1.1 Business Market Insights Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights
2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
  • 3.2.1 Hypothesis formulation:
  • 3.2.2 Macro-economic factor analysis:
  • 3.2.3 Developing base number:
  • 3.2.4 Data Triangulation:
  • 3.2.5 Country level data:

4. North America RNAi Therapeutics Market Landscape

4.1 Market Overview
4.2 Porter's Five Forces Analysis
  • 4.2.1 Bargaining Power of Suppliers
  • 4.2.2 Bargaining Power of Buyers
  • 4.2.3 Threat of New Entrants
  • 4.2.4 Competitive Rivalry
  • 4.2.5 Threat of Substitutes
4.3 Ecosystem Analysis
  • 4.3.1 Raw Material Suppliers
  • 4.3.2 Manufacturers
  • 4.3.3 Distributors/Suppliers
  • 4.3.4 End Users

5. North America RNAi Therapeutics Market – Key Market Dynamics

5.1 Growth Drivers
  • 5.1.1 RNAi Therapeutics in Cancer Therapy
5.2 Market Opportunities
  • 5.2.1 Imaging Modalities for RNAi Therapeutics for RNAi Therapeutics
5.3 Future Trends
  • 5.3.1 Rising Research & Development (R&D) activity
5.4 Impact of Drivers and Restraints

6. North America RNAi Therapeutics Market Regional Analysis

6.1 North America RNAi Therapeutics Market Overview
6.2 North America RNAi Therapeutics Market Revenue 2017-2027 (US$ Million)
6.3 North America RNAi Therapeutics Market Forecast Analysis

7. North America RNAi Therapeutics Market Analysis – by Molecule Type

7.1 Small Interfering RNAs
  • 7.1.1 Overview
  • 7.1.2 Small Interfering RNAs: North America RNAi Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
7.2 MicroRNA
  • 7.2.1 Overview
  • 7.2.2 MicroRNA: North America RNAi Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)

8. North America RNAi Therapeutics Market Analysis – by Application

8.1 Genetic Disorders
  • 8.1.1 Overview
  • 8.1.2 Genetic Disorders: North America RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
8.2 Oncology
  • 8.2.1 Overview
  • 8.2.2 Oncology: North America RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
8.3 Neurodegenerative Disorders
  • 8.3.1 Overview
  • 8.3.2 Neurodegenerative Disorders: North America RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
8.4 Cardiovascular
  • 8.4.1 Overview
  • 8.4.2 Cardiovascular: North America RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
8.5 Respiratory Disorders
  • 8.5.1 Overview
  • 8.5.2 Respiratory Disorders: North America RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
8.6 Infectious Diseases
  • 8.6.1 Overview
  • 8.6.2 Infectious Diseases: North America RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
8.7 Renal Diseases
  • 8.7.1 Overview
  • 8.7.2 Renal Diseases: North America RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)

9. North America RNAi Therapeutics Market Analysis – by Route of Administration

9.1 Intradermal Injections
  • 9.1.1 Overview
  • 9.1.2 Renal Diseases: North America RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
9.2 Pulmonary Delivery
  • 9.2.1 Overview
  • 9.2.2 Renal Diseases: North America RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
9.3 Intravenous Injections
  • 9.3.1 Overview
  • 9.3.2 Renal Diseases: North America RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
9.4 Intraperitoneal Injections
  • 9.4.1 Overview
  • 9.4.2 Renal Diseases: North America RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)

10. North America RNAi Therapeutics Market – North America Analysis

10.1 North America
  • 10.1.1 North America RNAi Therapeutics Market Breakdown, by Key Country, 2020 and 2027 (%)
  • 10.1.1.1 North America RNAi Therapeutics Market – Revenue and Forecast Analysis – by Country
  • 10.1.1.1 US: North America RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
    • 10.1.1.1.1 US: North America RNAi Therapeutics Market Breakdown, by Molecule Type
    • 10.1.1.1.2 US: North America RNAi Therapeutics Market Breakdown, by Application
    • 10.1.1.1.3 US: North America RNAi Therapeutics Market Breakdown, by Route of Administration
  • 10.1.1.2 Canada: North America RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
    • 10.1.1.2.1 Canada: North America RNAi Therapeutics Market Breakdown, by Molecule Type
    • 10.1.1.2.2 Canada: North America RNAi Therapeutics Market Breakdown, by Application
    • 10.1.1.2.3 Canada: North America RNAi Therapeutics Market Breakdown, by Route of Administration
  • 10.1.1.3 Mexico : North America RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
    • 10.1.1.3.1 Mexico : North America RNAi Therapeutics Market Breakdown, by Molecule Type
    • 10.1.1.3.2 Mexico : North America RNAi Therapeutics Market Breakdown, by Application
    • 10.1.1.3.3 Mexico : North America RNAi Therapeutics Market Breakdown, by Route of Administration

11. Competitive Landscape

11.1 Heat Map Analysis
11.2 Company Positioning and Concentration

12. North America RNAi Therapeutics Market Industry Landscape

12.1 Overview
12.2 Mergers and Acquisitions
12.3 Agreements, Collaborations, and Joint Ventures
12.4 New Product Launches
12.5 Expansions and Other Strategic Developments

13. Company Profiles

13.1 Alnylam Pharmaceuticals, Inc
  • 13.1.1 Key Facts
  • 13.1.2 Business Description
  • 13.1.3 Products and Services
  • 13.1.4 Financial Overview
  • 13.1.5 SWOT Analysis
  • 13.1.6 Key Developments
13.2 Arrowhead Pharmaceuticals, Inc
  • 13.2.1 Key Facts
  • 13.2.2 Business Description
  • 13.2.3 Products and Services
  • 13.2.4 Financial Overview
  • 13.2.5 SWOT Analysis
  • 13.2.6 Key Developments
13.3 Quark
  • 13.3.1 Key Facts
  • 13.3.2 Business Description
  • 13.3.3 Products and Services
  • 13.3.4 Financial Overview
  • 13.3.5 SWOT Analysis
  • 13.3.6 Key Developments
13.4 Rexahn Pharmaceuticals, Inc
  • 13.4.1 Key Facts
  • 13.4.2 Business Description
  • 13.4.3 Products and Services
  • 13.4.4 Financial Overview
  • 13.4.5 SWOT Analysis
  • 13.4.6 Key Developments
13.5 Arbutus Biopharma
  • 13.5.1 Key Facts
  • 13.5.2 Business Description
  • 13.5.3 Products and Services
  • 13.5.4 Financial Overview
  • 13.5.5 SWOT Analysis
  • 13.5.6 Key Developments

14. Appendix

14.1 About Business Market Insights

The List of Companies - N Market

The List of Companies - North America RNAi Therapeutics Market

  1. Alnylam Pharmaceuticals, Inc
  2. Arrowhead Pharmaceuticals, Inc
  3. Quark
  4. Rexahn Pharmaceuticals, Inc
  5. Arbutus Biopharma
north-america-rnai-therapeutics-market